Cystagon

PreclinicalSmall molecule

Amgen

Cystagon is one of 40 small molecule programs targeting Cystinosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystinosisActive, not recruiting

SchizophreniaActive, not recruiting

CystinosisPhase 1/Phase 2

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

4 2

Resotran

Takeda

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Zocor

OOrganon and Co

Preclinical

6 5

Depakote

Ibrance

Lunesta

3 8

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystinosis3 trials

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Completed· Amgen logo

Amgen·Phase 3·NCT01733316·41 enrolled

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Completed· Amgen logo

Amgen·Phase 3·NCT01000961·43 enrolled

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Completed· Amgen logo

Amgen·Phase 1/2·NCT00872729·9 enrolled

Schizophrenia1 trial

An Open Trial of Cysteamine Treatment in Schizophrenia

Terminated·—·N/A·NCT01139125·3 enrolled

Lip1 trial

Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 4·NCT00028262·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cystagon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cystagon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cystagon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Amgen

Cystagon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystinosis3 trials

Schizophrenia1 trial

Lip1 trial

References

Drug Info

Quick Facts

Related News